Angion Biomedica Corp. (ANGN)
1.00
0.00 (0.00%)
At close: Jun 01, 2023, 8:00 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 30.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.19M |
| EPS (ttm) | -10.11 |
| PE Ratio (ttm) | -0.09891196834817013 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 224,803 |
| Avg. Volume (20D) | 9,772 |
| Open | 1.06 |
| Previous Close | 1.00 |
| Day's Range | 1.00 - 1.00 |
| 52-Week Range | 1.00 - 20.40 |
| Beta | 0.60 |
About ANGN
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 3
Stock Exchange NASDAQ
Ticker Symbol ANGN
Website https://www.angion.com